In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

Debt Facility In connection with the New JV, Ganfeng has agreed to provide Lithium Argentina with a $130 million, six-year debt facility bearing interest at SOFR plus 2.5%. The Debt Facility enhances ...

Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date: Four ...

Lithium Argentina AG. ("Lithium Argentina" or the "Company") (TSX: LAR) (NYSE: LAR) is pleased to announce the execution of a framework agreement (the ...

Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) ...

Raising Full Year 2025 Gross Originations Outlook Gross Originations, Revenue and Adjusted EBITDA Growth to Continue In Third ...

Advanced Reactor Pilot Program launched by DOE to expedite authorization and commercialization of advanced nuclear reactor designs. Terrestrial Energy’s selection set to acceler ...

Members have espoused racist and antisemitic views and repeatedly praised Adolf Hitler and the Nazi party. They’ve raised ...

In May 2025, the DSMB recommended continuation of the trial as planned without any modification and clearance to proceed to the next dosing level, from the 5mg/kg dose of PMN310 in the first cohort to ...

Second Quarter 2025 Financial and Operating Results: ...

U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: ...

Q2 2025 revenue increased 20% YoY to $6.9 million, H1 2025 revenue increased 11% YoY to $13.7 million ●Significant turnaround ...